Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Targeted drug development for Autism Spectrum Disorder (ASD) has faced significant challenges and lack of progress.
• The International Society for Computational Biology and Medicine (ISCTM) and the European College of Neuropsychopharmacology (ECNP) established the ASD Working Group in 2017 to address these issues.

Purpose of the Study:

• Identify key barriers hindering therapeutic progress in ASD research.
• Recommend research strategies to advance the development of novel ASD therapeutics.
• Outline goals for next-generation biomedical interventions for ASD core features.

Main Methods:

• Convened international experts from academia, regulatory bodies, and industry.
• Conducted multiple meetings, teleconferences, and subgroup communications.
• Gathered diverse perspectives on lessons learned, current challenges, and future research directions.

Main Results:

• Identified major barriers including ASD heterogeneity, lack of validated biomarkers, need for improved clinical endpoints, target prioritization, and comorbidities.
• Highlighted optimism for therapeutic advancements due to progress in basic ASD neuroscience.
• Emphasized the potential of leveraging genetic data, intermediate phenotypes, digital phenotyping, big data analytics, refined endpoints, and early intervention.

Conclusions:

• Substantial prospects exist for breakthrough treatments for ASD core symptoms.
• Recommendations include prioritizing and expanding research funding for translational clinical ASD therapeutic research.
• A concerted effort is needed to overcome existing challenges and accelerate therapeutic development in ASD.